Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus

TARANEH MEHRANI and MICHELLE PETRI
The Journal of Rheumatology January 2011, 38 (1) 64-68; DOI: https://doi.org/10.3899/jrheum.100568
TARANEH MEHRANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHELLE PETRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mpetri@jhmi.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

REFERENCES

  1. 1.↵
    1. Fanopoulos D,
    2. Teodorescu MR,
    3. Varga J,
    4. Teodorescu M
    . High frequency of abnormal levels of IgA anti-ß2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998;25:675–80.
    OpenUrlPubMed
  2. 2.↵
    1. Tsutsumi A,
    2. Matsuura E,
    3. Ichikawa K,
    4. Fujisaku A,
    5. Mukai M,
    6. Koike T
    . IgA class anti-ß2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998;25:74–8.
    OpenUrlPubMed
  3. 3.↵
    1. Cucurull E,
    2. Gharavi AE,
    3. Diri E,
    4. Mendez E,
    5. Kapoor D,
    6. Espinoza LR
    . IgA anticardiolipin and anti-ß2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55–60.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Danowski A,
    2. Kickler T,
    3. Petri M
    . Anti-ß2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 2006;33:1775–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Lee S,
    2. Cho M,
    3. Joo Y,
    4. Kim W,
    5. Hong Y,
    6. Min J,
    7. et al.
    Isotypes of anti-ß2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:520–4.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Lakos G,
    2. Kiss E,
    3. Regeczy P,
    4. Tarján P,
    5. Soltész P,
    6. Zeher M,
    7. et al.
    Isotype distribution and clinical relevance of anti-ß2-glycoprotein I antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574–9.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Diri E,
    2. Cucurull E,
    3. Gharavi AE,
    4. Kapoor D,
    5. Mendez EA,
    6. Scopelitis E,
    7. et al.
    Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and anti-ß2-glycoprotein I is the most frequent isotype. Lupus 1999;9:33–41.
    OpenUrlCrossRef
  8. 8.↵
    1. Tan EM,
    2. Cohen AS,
    3. Fries JF,
    4. Masi AT,
    5. McShane DJ,
    6. Rothfield NF,
    7. et al.
    The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hochberg MC
    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Petri M,
    2. Rheinschmidt M,
    3. Whiting-O’Keefe Q,
    4. Hellmann D,
    5. Corash L
    . The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and cardiolipin antibody level. Ann Intern Med 1987;106:524–31.
    OpenUrlPubMed
  11. 11.↵
    1. Somers E,
    2. Magder LS,
    3. Petri M
    . Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J Rheumatol 2002;29:2531–6.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Petri M,
    2. Kim MY,
    3. Kalunian KC,
    4. Grossman J,
    5. Hahn BH,
    6. Sammaritano LR,
    7. et al.
    Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Chang CH,
    4. Urowitz MB,
    5. the Committee on Prognosis Studies in SLE
    . Development of the Disease Activity Index: the SLEDAI. Arthritis Rheum 1992;35:630–40.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.
    Systemic Lupus International Collaborative Clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;29:1820–1.
    OpenUrl
  15. 15.↵
    1. Bertolaccini ML,
    2. Atsumi T,
    3. Contreras AE,
    4. Khamashta MA,
    5. Hughes GRV
    . The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637–43.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Carmo-Pereira S,
    2. Bertolaccini ML,
    3. Escudero-Contreras A,
    4. Khamashta MA
    . Value of IgA anticardiolipin and anti-ß2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540–3.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Samarkos M,
    2. Davies KA,
    3. Gordon C,
    4. Loizou S
    . Clinical significance of IgA anticardiolipin and anti-ß2-gpi antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006;25:199–204.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Cervera R,
    2. Piette J,
    3. Font J,
    4. Khamashta MA,
    5. Shoenfeld Y,
    6. Camps MT,
    7. et al.
    Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019–27.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Asherson RA,
    2. Cervera R
    . Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol 2007;32:153–8.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ramos-Casals M,
    2. Nardi N,
    3. Brito-Zeron P,
    4. Aguilo S,
    5. Gil V,
    6. Delgado G,
    7. et al.
    Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006;35:312–21.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Fauchais AL,
    2. Lambert M,
    3. Launay D,
    4. Michon-Pasturel U,
    5. Queyrel V,
    6. Nguyen N,
    7. et al.
    Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 2004:13:245–8.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Cervera R,
    2. Garcia-Carrasco M,
    3. Font J,
    4. Ramos M,
    5. Reverter JC,
    6. Muñoz FJ,
    7. et al.
    Antiphospholipid antibodies in primary Sjogren’s syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 1997;15:361–5.
    OpenUrlPubMed
  23. 23.↵
    1. Merkel PA,
    2. Chang Y,
    3. Pierangeli SS,
    4. Convery K,
    5. Harris EN,
    6. Polisson RP
    . The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576–83.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 1
1 Jan 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus
TARANEH MEHRANI, MICHELLE PETRI
The Journal of Rheumatology Jan 2011, 38 (1) 64-68; DOI: 10.3899/jrheum.100568

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus
TARANEH MEHRANI, MICHELLE PETRI
The Journal of Rheumatology Jan 2011, 38 (1) 64-68; DOI: 10.3899/jrheum.100568
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire